The most commonly reported side effects in Phase 2 trials were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation, which were generally mild to moderate and tended to improve over time
09/906,041, 09/559,799 and 10/919,603
Semaglutide works by mimicking the action of GLP-1, a hormone that increases insulin release, decreases sugar production by the liver, and decreases appetite
The recent conclusion of major phase 3 trials for the oral glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide represents another notable setback in this endeavor ( The observed discrepancy between promising preclinical and epidemiological data and the negative outcomes of a large-scale clinical trial in established Alzheimers disease (AD) necessitates a thorough analysis